Transparency
Market Research Reports incorporated a definite business overview and
investigation inclines on “Rubella
Diagnostic Testing Market”.
This report likewise incorporates more illumination about fundamental
review of the business including definitions, requisitions and
worldwide business sector industry structure. Rubella or German
measles is a contagious and acute viral infection caused by the
rubella virus. Generally, rubella infection occurs most often in
young adults and children. While the rubella infection is typically
mild in children, this disease has serious consequences in pregnant
women causing congenital defects and fetal death.
Browse
Full Report with TOC:
http://www.transparencymarketresearch.com/rubella-diagnostic-testing-market.html
Some
of the diagnostic testing techniques usually adopted for the
diagnosis of rubella are as follows:
- Clinical evaluation
- Serological testing
- Immunoassays
- Monoclonal antibodies
- Latex slide agglutination test
- Flow cytometry
At
present, there is no standard drug therapy available for treating
rubella. However, MMR vaccine, which is an immunization vaccine, is
administered to children for protecting against measles, mumps, and
rubella. The goals of medications given to the patients are only to
prevent complications and to reduce morbidity.
In
terms of geography, Europe is the leading market in rubella
diagnostic testing market due to the high susceptibility to rubella.
It has been stated that, as of 2004, the U.S. was declared free of
rubella and the transmission of the rubella virus was halted across
the regions of the Americas in 2009. Furthermore, on January 2014,
the PAHO (Pan American Health Organization) and WHO (World Health
Organization) declared the Latin American country, Colombia free of
rubella. However, it has been observed, epidemics of rubella still
occur in developing regions such as South East Asia and Africa, where
the vaccine for rubella is not available or accessible. The countries
with the largest number of cases in 2012 were Syria, Tajikistan,
Macedonia, Timor-Leste and Thailand.
Some
of the primary factors driving the growth of rubella diagnostic
testing market are low awareness rate among population and
introduction of advance point of care diagnostic technologies. For
instance, Bio-Rad Laboratories, Inc., a global company engaged in the
development and commercialization of clinical diagnostic and life
science research products introduced BioPlex 2200 MMRV (Measles,
Mumps, Rubella, and Varicella-Zoster Virus) IgG kit for better
diagnosis and prevention of these diseases. This kit is designed to
provide simultaneous results for the four diseases i.e. Measles,
Mumps, Rubella, and Varicella-Zoster Virus (chicken pox). Thus, the
introduction of promising point of care diagnostic kits in this
market is likely to boosts the overall rubella diagnostic testing
market due to the high success and effectiveness rate of the
potential molecules. Furthermore, increasing government support for
developing novel therapies and vaccines; along with high research and
development initiatives on the development of advance diagnostic
techniques are expected to fuel the growth of this market. In
addition, technological breakthrough such as microfluidic point of
care diagnostic kits and increased focus on retaining superior
quality of life are some of the factors that might contribute to the
growth of this market. However, rise in overall healthcare
expenditure and product availability are some of the
market-restraining factors that might hinder the growth of the
rubella diagnostic testing market in the near future.
At
present, the rubella diagnostic testing market is an burgeoning
market venture; specifically in regions such as Africa and South East
Asia due to the low rate of vaccine coverage in these regions.
However, at present this market is highly fragmented owing to the
involvement of many established and emerging players. Some of the key
players engaged in this market are Abbott Laboratories, Beckman
Coulter Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., F.
Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc.,
Ortho Clinical Diagnostics and Siemens AG, amongst others.
Read
More Reports on Medical Devices Markets:
http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
This
research report analyzes this market depending on its market
segments, major geographies, and current market trends. Geographies
analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This
report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This
report is a complete study of current trends in the market, industry
growth drivers, and restraints. It provides market projections for
the coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
Enquiry
before Buying @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2935
About
Us
Transparency
Market Research is a market intelligence company providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers.
Followed
LinkedIn
:-https://www.linkedin.com/today/post/article/20140808045047-349336221-rubella-diagnostic-testing-market-2014-2020
Contact:
Transparency
Market Research
90
State Street,
Suite
700,
Albany
NY — 12207
United
States
Tel:
+1-518-618-1030
USA — Canada
Toll Free 866-552-3453
Browse
Market Research Blogs:
0 comments:
Post a Comment